Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup
Nearly 4 years after Roche agreed to pay the research tab for a team of investigators at Versant Ventures’ discovery group Inception Sciences to see if they could come up with a viable, IND-ready compound to take into the clinic for remyelination work in multiple sclerosis, the pharma giant has grabbed its star candidate. And the team they helped fund is now being spun out into a startup focused on neuroregeneration with the blessings of Versant and a commitment of $25 million to help fund their new, independent existence.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.